अApnaFunda
Menu

ABBOTT INDIA LIMITED (ABBOTINDIA)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.82 / 100
Profitability 92Growth 53Balance sheet 100
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.52 / 100
Price 58Earnings 55FII/DII 43

Passes these screensCash RichQuality CompounderDebt-light & profitable

Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹26,680 latest close · +5.4% over the last 90 sessions

₹25,000₹26,000₹27,000₹28,000Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹25,000₹26,000₹27,000₹28,000Jul 3Sep 4Nov 9

₹26,680 month-end · −9.2% over 12 months

₹26,000₹28,000Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹26,000₹28,000Nov '25May '26Nov '26

₹26,680 month-end · +14.7% over 3 years

₹25,000₹30,000₹35,000Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹25,000₹30,000₹35,000Nov '23May '25Nov '26

₹26,680 month-end · +238.4% since Jan '19

₹10,000₹20,000₹30,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹10,000₹20,000₹30,000Jan '19Dec '22Nov '26

52-week range ₹24575.00 to ₹29955.00 · 1-year volatility 21.3%

Was the rally earned?

-9%share price, 1 yearLower P/E held it back

Earnings helped, the multiple did not.

  • Per-share earnings added 10 points, but investors now pay less per rupee of profit (P/E 43.0x to 35.1x), which took 19 points back.
  • The share count barely moved.
Net profit growth: +10 pts. Points of the price return explained by net profit growing (or shrinking).+10 ptsNet profit growthP/E change: −19 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−19 ptsP/E changeShare price: −9%−9%Share priceNet profit growth: +10 pts. Points of the price return explained by net profit growing (or shrinking).+10ProfitP/E change: −19 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−19P/EShare price: −9%−9%Share price
Net profit growth+10 ptsNet profit rose about 11%, which lifts the price.
P/E change-19 ptsThe P/E fell from 43.0x to 35.1x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+15%share price, 3 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 57 points, but investors now pay less per rupee of profit (P/E 52.1x to 35.1x), which took 42 points back.
  • The share count barely moved.
Net profit growth: +57 pts. Points of the price return explained by net profit growing (or shrinking).+57 ptsNet profit growthP/E change: −42 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−42 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +15%+15%Share priceNet profit growth: +57 pts. Points of the price return explained by net profit growing (or shrinking).+57ProfitP/E change: −42 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−42P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +15%+15%Share price
Net profit growth+57 ptsNet profit rose about 70%, which lifts the price.
P/E change-42 ptsThe P/E fell from 52.1x to 35.1x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+43%share price, 5 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 102 points, but investors now pay less per rupee of profit (P/E 57.4x to 35.1x), which took 59 points back.
  • The share count barely moved.
Net profit growth: +102 pts. Points of the price return explained by net profit growing (or shrinking).+102 ptsNet profit growthP/E change: −59 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−59 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: +43%+43%Share priceNet profit growth: +102 pts. Points of the price return explained by net profit growing (or shrinking).+102ProfitP/E change: −59 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−59P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: +43%+43%Share price
Net profit growth+102 ptsNet profit rose about 134%, which lifts the price.
P/E change-59 ptsThe P/E fell from 57.4x to 35.1x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-32.9%recovered 2023-06
1-year volatility21.3%annualised
Beta vs sector index0.573-year daily, correlation 0.37
Volume spikes0last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−10%−20%−30%2020202120222023202420252026−31.6% 0%−10%−20%−30%2020202220242026−31.6%
Largest drawdowns

-32.9% (2021-10 peak to 2022-02 low, recovered 2023-06)

-29.4% (2025-06 peak to 2026-04 low, not yet recovered)

-23.0% (2020-05 peak to 2021-02 low, recovered 2021-07)

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

35.1xP/E todayNear its historic low
Against its own history4th percentile
CheapestMedian 50.5xDearest

Usual range 37.9x to 58.3x since 2019-01.

Against Health Technology35.1x vs 37.0x
This company
35.1x
Sector median
37.0x

5% below the Health Technology median.

16.7x38.4x60.1x81.8xJan '19Aug '20Mar '22Oct '23May '25Nov '2616.7x38.4x60.1x81.8xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE97thflat vs a year ago
  • Op. margin87th▲ 8 pts vs a year ago
  • Revenue growth31st▼ 31 pts vs a year ago
  • EPS growth54th▼ 8 pts vs a year ago
  • Debt/equity ↓80th▲ 5 pts vs a year ago
  • Cash cycle ↓93rdflat vs a year ago
  • P/E ↓55th▲ 21 pts vs a year ago
  • 12M momentum27th▼ 54 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~18%annual earnings growth implied by the priceIn line with delivered growth

At P/E of 35.1x, a holder earning 12%/yr needs earnings to grow about 18.0%/yr for 10 years, then trade at 15x.

Delivered20.5%/yrEPS, last 10 fiscal years · fitted trend
Gap−2.5 ptsimplied minus delivered
Rank580thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

0%16%31% Jan 2019Nov 2026 0%16%31% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x19.0%20.1%21.2%
15x16.9%18.0%19.1%
20x14.2%15.2%16.2%

Drag a slider to test other assumptions

Implied: 18.0%/yr

Looking back

  • Jan 2020Price implied 27%/yr; EPS has since grown 19%/yr (7.0 yrs)
  • Jan 2021Price implied 25%/yr; EPS has since grown 17%/yr (6.0 yrs)
  • Jan 2022Price implied 24%/yr; EPS has since grown 18%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹26680.00
P/E
35.1x
ROCE
45.0%
Market Cap
₹56695 cr
Revenue (TTM)
₹7005 cr
P/S
8.1x
P/B
11.9x
ROE
33.8%
Operating Margin
29.0%
Debt / Equity
0.0x
Promoter Holding
75.0%
12M Momentum
-9.2%

52-week range

₹24575.00₹29955.00
39% of the way from its 52-week low to its high

Price risk

1Y volatility
21.3%
Beta vs sector
1-year daily
0.35

Balance sheet & cash

Interest cover
operating profit ÷ interest
87.3x
Cash from profit, 3Y
operating cash flow ÷ net profit
0.85x
Share count, 1Y
unchanged

Are profits backed by cash?

7 of 7checks within rangeAll clear
Other income reliance13%Within range

Other income as a share of pre-tax profit (trailing twelve months): 13.5%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate26%Within range

Median quarterly effective tax rate over about 2.5 years: 25.5%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion0.85xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 0.85x (cash from operations ₹3,544 cr, net profit ₹4,167 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history-3 daysWithin range

Debtor days are below the median of the previous three fiscal years by 3 days (19 vs 22). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress2% of fixed assetsWithin range

Capital work-in-progress is 2% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-5 days / 2 yrsWithin range

Days payable changed by -5 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, institutional and promoter holdings were broadly unchanged.
  • The number of shareholders rose from 68,885 to 78,320 (+14%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters75.0%75.0%0.0 pts
FIIs0.2%0.4%+0.2 pts
DIIs8.8%8.8%-0.1 pts
Public and others16.0%15.8%-0.2 pts

Number of shareholders

78,320shareholders+14% since Sep '23
68k71k75k78k Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 68,885
Dec '23: 72,252
Mar '24: 69,382
Jun '24: 71,588
Sep '24: 69,449
Dec '24: 67,892
Mar '25: 69,934
Jun '25: 67,584
Sep '25: 71,199
Dec '25: 75,801
Mar '26: 75,866
Jun '26: 78,320
 68k71k75k78k Sep '23Sep '24Sep '25Jun '26
Sep '23: 68,885
Dec '23: 72,252
Mar '24: 69,382
Jun '24: 71,588
Sep '24: 69,449
Dec '24: 67,892
Mar '25: 69,934
Jun '25: 67,584
Sep '25: 71,199
Dec '25: 75,801
Mar '26: 75,866
Jun '26: 78,320

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−9.7%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like ABBOTT INDIA LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −21% to +13% vs the market, against −7% for all non-financial companies in the same months.
  • The gap against the base rate (−2.7%, 80% range −12.3% to +1.8%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−60%−40%−20%0%+20%+40%+60%+80%
PGHH · Sep 2025: −52.2% vs market
CLEAN · Feb 2025: −47.8% vs market
SANOFI · Jun 2025: −46.6% vs market
PIIND · Jul 2025: −38.6% vs market
INDIAMART · Oct 2025: −36.1% vs market
IRCTC · Oct 2025: −35.9% vs market
VGUARD · Jan 2021: −31.3% vs market
PAGEIND · Dec 2024: −28.1% vs market
ITC · Mar 2025: −26.3% vs market
INFY · Jun 2022: −23.9% vs market
EMAMILTD · Aug 2024: −23.5% vs market
DABUR · Dec 2022: −21.9% vs market
BAJAJ-AUTO · Aug 2020: −21.1% vs market
LTTS · Mar 2024: −20.8% vs market
SUMICHEM · Jul 2022: −20.3% vs market
SANOFICONR · Sep 2025: −19.9% vs market
HINDUNILVR · Jul 2025: −19.4% vs market
UBL · Apr 2020: −19.2% vs market
OFSS · Apr 2021: −17.1% vs market
ALKYLAMINE · May 2025: −17.0% vs market
BRITANNIA · Feb 2020: −16.8% vs market
TCS · Jun 2022: −15.8% vs market
BERGEPAINT · Mar 2025: −15.8% vs market
INGERRAND · Oct 2024: −13.3% vs market
ATUL · May 2021: −12.3% vs market
PGHL · Jan 2025: −7.1% vs market
ERIS · Feb 2023: −6.8% vs market
SCHAEFFLER · May 2024: −6.0% vs market
ASIANPAINT · Apr 2025: −5.5% vs market
UNITDSPR · Oct 2024: −3.7% vs market
COLPAL · Apr 2022: −2.3% vs market
KIMS · Mar 2023: −1.1% vs market
3MINDIA · Aug 2025: +0.6% vs market
MARICO · Nov 2020: +3.8% vs market
CROMPTON · Nov 2020: +4.1% vs market
PIDILITIND · Oct 2025: +6.9% vs market
CRISIL · Jan 2021: +8.0% vs market
GLAXO · Nov 2023: +14.1% vs market
LALPATHLAB · Jul 2025: +14.8% vs market
NESTLEIND · May 2025: +16.1% vs market
GILLETTE · Oct 2023: +16.7% vs market
HAVELLS · Sep 2020: +23.8% vs market
AJANTPHARM · Mar 2023: +24.2% vs market
CAMS · Nov 2023: +36.1% vs market
EICHERMOT · Dec 2024: +43.7% vs market
SUPREMEIND · Dec 2022: +46.0% vs market
CUMMINSIND · Jul 2025: +47.3% vs market
BEL · Aug 2023: +52.6% vs market
INOXINDIA · Jul 2025: +54.7% vs market
COHANCE · Oct 2023: +62.9% vs market
Similar setups −9.7%All companies −7.0%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months

Similar setups' median
−9.7%
All companies' median
−7.0%
Beat the market
36% vs 42%

50 past situations · 50 companies · 32 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
IRCTC
Consumer Services		 Oct 2025 43x49% −13%−16% −36%
PGHH
Consumer Non-Durables		 Sep 2025 55x104% −15%−16% −52%
SANOFI
Health Technology		 Jun 2025 35x49% −2%−14% −47%
3MINDIA
Producer Manufacturing		 Aug 2025 57x41% −14%−15% +1%
MARICO
Consumer Non-Durables		 Nov 2020 47x43% +2%−3% +4%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
GLAXO
Health Technology		 Nov 2023 45x36% +24%−2% +14%
CRISIL
Commercial Services		 Jan 2021 40x42% +12%−8% +8%
PIDILITIND
Process Industries		 Oct 2025 67x30% −8%−10% +7%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, P/S and drawdown from 12-month high. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to ABBOTT INDIA LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

GILLETTE INDIAGILLETTE
Consumer Non-Durables
79%similar
operating marginvolatility
HINDUSTAN AERONAUTICSHAL
Electronic Technology
78%similar
P/Eoperating margin
PIDILITE INDUSTRIESPIDILITIND
Process Industries
72%similar
revenue growthdebt/equity
ORACLE FINANCIAL SERVICES SOFTOFSS
Technology Services
69%similar
ROCEmarket cap
SCHAEFFLER INDIASCHAEFFLER
Producer Manufacturing
68%similar
market caprevenue
GLAXOSMITHKLINE PHARMACEUTICALGLAXO
Health Technology
84%similar
market capROCE
AJANTA PHARMAAJANTPHARM
Health Technology
68%similar
market capP/E
CAPLIN POINT LABORATORIESCAPLIPOINT
Health Technology
62%similar
EPS growthoperating margin

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jun '20

  1. AprPriceFell 29% from the Jun 2025 peak to the Apr 2026 low.
  2. AprPriceVolume reached 5.8x its 50-day median on 2026-04-27; price +1.0% that day.
  3. NovPriceVolume reached 8.5x its 50-day median on 2025-11-06; price +0.3% that day.
  4. SepValuationP/E fell below the 10th percentile of its own history to date (41.9x).
  5. JunPriceVolume reached 7.9x its 50-day median on 2025-06-27; price +5.7% that day.
  6. FebPriceVolume reached 10.6x its 50-day median on 2025-02-06; price +4.6% that day.
  7. JanValuationP/E fell below the 10th percentile of its own history to date (42.3x).
  8. AugPriceVolume reached 6.5x its 50-day median on 2024-08-08; price -3.3% that day.
Show 22 earlier events
  1. JunResultsRevenue (TTM) reached a new high of ₹5,849 cr.
  2. MarPeer rankSlipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
  3. FebValuationP/E crossed above the 90th percentile of its own history to date (62.2x).
  4. FebPriceVolume reached 6.5x its 50-day median on 2024-02-02; price +8.4% that day.
  5. AugPriceVolume reached 6.2x its 50-day median on 2023-08-10; price +0.6% that day.
  6. JunResultsRevenue (TTM) reached a new high of ₹5,349 cr.
  7. JunPriceRegained the 2021-10 peak, 16 months after the low.
  8. JunPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 2nd quartile).
  9. SepPriceVolume reached 6.1x its 50-day median on 2022-09-29; price +5.8% that day.
  10. JunResultsRevenue (TTM) reached a new high of ₹4,919 cr.
  11. JunPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
  12. JunPriceVolume reached 5.1x its 50-day median on 2022-06-02; price +3.4% that day.
  13. FebPriceFell 33% from the Oct 2021 peak to the Feb 2022 low.
  14. FebPriceVolume reached 7.9x its 50-day median on 2022-02-09; price +7.1% that day.
  15. OctPriceVolume reached 8.7x its 50-day median on 2021-10-04; price +4.9% that day.
  16. SepPriceVolume reached 5.4x its 50-day median on 2021-09-29; price -6.9% that day.
  17. JunResultsRevenue (TTM) reached a new high of ₹4,310 cr.
  18. JunPeer rankSlipped to the 3rd quartile of Health Technology on EPS growth (from the 2nd quartile).
  19. JunPriceVolume reached 5.2x its 50-day median on 2021-06-08; price +0.4% that day.
  20. DecPriceVolume reached 7.5x its 50-day median on 2020-12-11; price +3.4% that day.
  21. JunResultsRevenue (TTM) reached a new high of ₹4,093 cr.
  22. JunPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history60 months · 2021-12 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1135.1x₹7005 cr33.8%45.0%0.0x
2026-1033.7x₹7005 cr33.8%45.0%0.0x
2026-0935.7x₹7005 cr33.8%45.0%0.0x
2026-0835.4x₹6929 cr32.5%45.0%0.0x
2026-0738.1x₹6929 cr32.5%45.0%0.0x
2026-0634.0x₹6929 cr32.5%45.0%0.0x
2026-0536.6x₹6824 cr36.0%46.0%0.0x
2026-0434.7x₹6824 cr36.0%46.0%0.0x
2026-0335.3x₹6824 cr36.0%46.0%0.0x
2026-0236.5x₹6714 cr35.6%46.0%0.0x
2026-0137.9x₹6714 cr35.6%46.0%0.0x
2025-1239.9x₹6714 cr35.6%46.0%0.0x
2025-1143.0x₹6590 cr34.3%46.0%0.0x
2025-1041.5x₹6590 cr34.3%46.0%0.0x
2025-0941.9x₹6590 cr34.3%46.0%0.0x
2025-0846.2x₹6410 cr33.4%46.0%0.0x
2025-0750.5x₹6410 cr33.4%46.0%0.0x
2025-0652.4x₹6410 cr33.4%46.0%0.0x
2025-0547.4x₹6244 cr36.1%46.0%0.0x
2025-0446.7x₹6244 cr36.1%46.0%0.0x
2025-0347.8x₹6244 cr36.1%46.0%0.0x
2025-0249.1x₹6067 cr34.7%46.0%0.0x
2025-0142.3x₹6067 cr34.7%46.0%0.0x
2024-1248.1x₹6067 cr34.7%46.0%0.0x
2024-1146.5x₹5928 cr33.5%46.0%0.0x
2024-1048.6x₹5928 cr33.5%46.0%0.0x
2024-0948.9x₹5928 cr33.5%46.0%0.0x
2024-0852.2x₹5849 cr32.5%46.0%0.0x
2024-0749.1x₹5849 cr32.5%46.0%0.0x
2024-0647.7x₹5849 cr32.5%46.0%0.0x
2024-0556.6x₹5349 cr29.8%41.0%0.0x
2024-0457.8x₹5349 cr29.8%41.0%0.0x
2024-0359.3x₹5349 cr29.8%41.0%0.0x
2024-0262.2x₹5349 cr29.8%41.0%0.0x
2024-0156.7x₹5349 cr29.8%41.0%0.0x
2023-1250.0x₹5349 cr29.8%41.0%0.0x
2023-1152.1x₹5349 cr29.8%41.0%0.0x
2023-1049.0x₹5349 cr29.8%41.0%0.0x
2023-0950.7x₹5349 cr29.8%41.0%0.0x
2023-0850.5x₹5349 cr29.8%41.0%0.0x
2023-0752.6x₹5349 cr29.8%41.0%0.0x
2023-0651.2x₹5349 cr29.8%41.0%0.0x
2023-0556.5x₹4919 cr28.3%38.0%0.1x
2023-0458.0x₹4919 cr28.3%38.0%0.1x
2023-0357.4x₹4919 cr28.3%38.0%0.1x
2023-0252.5x₹4919 cr28.3%38.0%0.1x
2023-0154.1x₹4919 cr28.3%38.0%0.1x
2022-1255.6x₹4919 cr28.3%38.0%0.1x
2022-1152.6x₹4919 cr28.3%38.0%0.1x
2022-1050.0x₹4919 cr28.3%38.0%0.1x
2022-0949.8x₹4919 cr28.3%38.0%0.1x
2022-0848.7x₹4919 cr28.3%38.0%0.1x
2022-0752.0x₹4919 cr28.3%38.0%0.1x
2022-0648.8x₹4919 cr28.3%38.0%0.1x
2022-0553.3x₹4310 cr26.6%35.0%0.1x
2022-0451.3x₹4310 cr26.6%35.0%0.1x
2022-0353.2x₹4310 cr26.6%35.0%0.1x
2022-0252.8x₹4310 cr26.6%35.0%0.1x
2022-0148.3x₹4310 cr26.6%35.0%0.1x
2021-1258.6x₹4310 cr26.6%35.0%0.1x

Older months are in the live observatory.

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback